The efficacy and safety of Dimephosphone in patients with chronic cerebral ischemia

There is some data on the efficacy of the neuroprotective agent Dimephosphone in chronic cerebral ischemia (CCI), but no comparative studies have been conducted.

Objective: the aim of the study was to conduct a comparative study of the efficacy and safety of Dimephosphon therapy, administered intravenously over a 10-day course, in patients with CCI.

Material and methods. The study involved 52 patients with CCI who were undergoing inpatient treatment in the neurology department of the City Clinical Emergency Hospital No. 1 in Voronezh. The first (main) group included 28 patients with CCI who received basic therapy (antihypertensive, hypolipidemic, antiplatelet or anticoagulant therapy, correction of emotional status) and intravenous Dimephosphone once a day for 10 days. The second (control) group consisted of 24 patients who received only basic therapy. The effectiveness of the therapy was assessed using the asthenia scale (MFI-20), the Hospital Anxiety and Depression Scale (HADS), and the Tinetti scale.

Results. A significant (p<0.05) advantage was noted in the main group compared to the control group in terms of the analysed indicators. On the MFI-20 scale, the initial level of asthenic symptoms was 77.43±1.69 points in the main group and 77.00±1.89 points in the control group, which corresponds to significant asthenia. By the end of treatment, the indicators decreased to 47.96±1.55 and 61.46±1.38 points, respectively. Motor activity on the Tinetti scale was initially 33.21±2.06 points in the main group and 32.46±3.06 points in the comparison group. By the end of the treatment course, the main group showed a 38.51% increase in motor activity (up to 46±2.71 points). No similar dynamics were observed in the control group, and motor activity indicators were 33.62±2.62 points. The decrease in HADS scores at the end of treatment compared to baseline in the main group was 24.5% on the depression scale and 33.12% on the anxiety scale. In the comparison group, these same indicators decreased by 11.13% and 11.23%, respectively.

Conclusion. The results of the study indicate the efficiency and safety of therapy with Dimephosphone in patients with CCI.

1. Avrov MV, Alifirova VM, Kovalenko AV. Effect of complex therapy on cognitive impairment in patients with chronic cerebral ischemia. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2):23-7. doi: 10.17116/jnevro201911902123 (In Russ.).

2. Gusev EI, Chukanova EI, Chukanova AS. Chronic cerebrovascular insufficiency (risk factors, pathogenesis, clinical features, treatment). Moscow: AST 345; 2018. 187 p. (In Russ.).

3. Sattorova DA. Aspects of cerebral circulation in chronic cerebral ischemia. In: Education, science and technology: problems and prospects: Collection of scientific papers based on the materials of the international scientific and practical conference. Moscow; 2019. P. 242-5 (In Russ.).

4. Maximov ML, Malykhina AI, Shikaleva AA. Time-proved pharmacotherapy: from mechanisms to clinical efficacy. RMJ. 2020;(9):71-6 (In Russ.).

5. Konopleva OP, Sholomov II, Volzhenin VE, Shchukovsky NV. Neuroprotective therapy and the state of cerebral blood flow perfusion in chronic cerebral ischemia caused by arterial hypertension. Terra Medica Nova. 2007;1(45):10-2 (In Russ.).

6. Poluektov MG, Podymova IG, Golubev VL. Potentials of using Dimephosphone in neurology and neurosurgery. Doctor. ru. 2015;106-107(5-6):5-10 (In Russ.).

7. Tanashyan MM, Lagoda OV, Antonova KV. Chronic cerebrovascular diseases on the background of metabolic syndrome: new approaches to treatment. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(11):21-6 (In Russ.).

8. Danilova TV, Knni KS, Magsumova RL, et al. The efficacy of the anti-acidemic agent dimephosphone at the first rehabilitation stage in patients in the acute period of carotid-related ischemic stroke. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(3):44-51. doi: 10.17116/jnevro202112103144 (In Russ.).

9. Zakirova DR, Khuzina GR, Mamedov HI, et al. Neuroprotective therapy for chronic brain ischemia: clinical effects of the drug Dimephosphon. Sovremennaya meditsina = Modern Medicine. 2018;1(9):55-60 (In Russ.).

10. Poluektov MG, Podymova IG, Golubev VL. Experience of the drug dimephosphon in the treatment of non-motorized manifestations of dyscirculatory encephalopathy. Prakticheskaya meditsina = Practical Medicine. 2015;5(90):164-8 (In Russ.).

11. Danilov VI, Studentsova IA. Dimephosphon drug of choice in diseases of nervous system. Neurology, Terra Medica. 2000;(1):34 (In Russ.).

12. Ulyanova OV, Poedinok EYu. Venous encephalopathy. Own clinical observation. In: Emergency conditions in neurology: modern methods of diagnosis and treatment. Collection of articles and abstracts of the All-Russian scientific and practical conference. St. Petersburg: Military Medical Academy named after S.M. Kirov; 2017. 104 p. (In Russ.).